echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > [Medicine] after the Valsartan toxin gate, the Huahai losartan potassium API was questioned again, and the Huahai response met the requirements; the director of the CDC took bribes due to vaccines; the deputy director of the drug administration was "detained"

    [Medicine] after the Valsartan toxin gate, the Huahai losartan potassium API was questioned again, and the Huahai response met the requirements; the director of the CDC took bribes due to vaccines; the deputy director of the drug administration was "detained"

    • Last Update: 2018-11-13
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On November 6, the general office of Shaanxi provincial Party committee and the general office of Shaanxi provincial government issued new policies to promote the reform of drug review and approval system In order to promote the reform of review and approval system in Shaanxi Province, six innovative measures are put forward It is worth noting that the incentive mechanism implemented in the province clearly requires that the maximum amount of financial support for the first-class chemical new drugs in Shaanxi Province shall not exceed 20 million yuan; the maximum amount of financial support for the first-class traditional Chinese medicine new drugs shall not exceed 10 million yuan; the two-way subsidy shall be implemented for the major scientific and technological achievements successfully transformed on the spot; for the enterprises that have passed the consistency evaluation of generic drugs, each product of provincial finance shall be provided 3 million yuan will be awarded to drug manufacturers; those who have passed the consistency evaluation and transferred the approval number of drugs from other provinces to our province and produced in accordance with the law will enjoy the same support policy for drugs in the province 14 provinces announced the results of special purchase price negotiation, 47 anti-cancer drugs were selected, and 10 drugs were out of the market on November 8, Hainan and other provinces successively released the results of joint price negotiation of imported anti-cancer drugs by provincial alliance According to the price negotiation list, 47 anti-cancer drugs were successfully negotiated, 10 drugs were unsuccessful, and 24 drugs were undeclared, and the products that were not successfully negotiated and undeclared without special reasons were required to be suspended This time, foreign-funded enterprises adopted different strategies in drug pricing, that is, to occupy the market by rapidly reducing prices for new varieties of anticancer drugs; to mature, monopolized and step-by-step pressing products with generic drugs, some foreign-funded pharmaceutical enterprises chose to reduce prices to win the market; and to exclusive varieties, only a few enterprises reduced prices License separation has been carried out in many provinces Ten thousand private hospitals and clinics will make profits on November 7 The health and Health Commission of Liaoning Province issued a notice It is allowed for profit-making medical institutions to carry out medical related business activities such as drugs, devices, etc., and the place for medical activities shall be separated from other places for business activities According to the data of the health care Commission, by the end of May 2018, there were 32000 hospitals, including 12145 public hospitals and 19461 private hospitals At the same time, according to relevant media statistics, in 2017, the sales volume of drugs in three major terminals and six major markets in China reached 161.8 billion yuan, and the sales volume of drugs in private hospitals plus private clinics and village clinics was about 288.2 billion yuan As a result, industry insiders said that under the promotion of "reasonable license", if private hospitals and private clinics can be transformed into a large number of composite medical institutions for diagnosis and treatment and drug sales, the market potential is very huge In addition, Guizhou, Guangxi and Guangdong also issued the notice on promoting the reform of "separation of certificate and license" for health and family planning, accelerating the implementation of the reform of "separation of certificate and license" On November 7, Chongqing issued a notice on soliciting public opinions on the draft of detailed rules for implementing the reform of "separation of license and license" After valsartan toxin gate, Huahai losartan potassium API is questioned again On November 10, Huahai pharmaceutical issued a Clarification Announcement on the relevant report of "Sandoz recalled a batch of losartan hydrochlorothiazide tablets in the United States" It said that after analyzing the impurity content of more than 500 batches of losartan potassium samples produced from 2016 to 2018, the test results showed that the samples all met the limit standard of 0.18ppm calculated according to the limit requirements of valsartan NDEA provided by the European Union (according to Calculation of the maximum dose of 150mg listed in Europe) The NDEA content of losartan potassium involved in this recall batch of Novartis is only about 0.039ppm, which is also far lower than the above limit standard after the company's test Moreover, because of the vague content of the recall announcement of Novartis, the relevant facts are not clearly and completely stated, which seriously mislead investors At the beginning of November, the intermediate people's Court of Fuyang City adjudicated a bribery case That is to say, Yang Mou, the former director of Yingquan District CDC (now retired), was sentenced to three years' imprisonment, four years' probation and a fine of 200000 yuan for taking advantage of his position and accepting 260000 yuan from others and seeking benefits for others in selling vaccines It is reported that the case involved 10 companies, including Shenzhen Sanofi Pasteur, Beijing Kexing biology, tailing pharmaceutical and other well-known pharmaceutical companies In fact, in recent years, the bribery scandal of the director of the CDC has been exposed from time to time For example, on October 19, 2017, China judicial document network published the criminal ruling of the second instance of bribery of Li chuantao and the unit of Lixin County disease prevention and control center During his tenure as director of the disease control center of Lixin County, Li chuantao received nearly one million yuan of vaccine rebate and bribes from others Among them, vaccine enterprises such as North China Pharmaceutical Jintan biology and Changchun Changsheng biology have given Li chuantao kickbacks; on August 15, 2017, the people's Court of Xiashan District, Zhanjiang City, Guangdong Province announced the criminal judgment of Fengzhi in the first instance of bribery Feng Zhi, director of Zhanjiang CDC, took advantage of his position to receive 1 million yuan of property from Watson biology, zhenrui pharmaceutical, Guosheng biology and other relevant personnel for his own benefit In addition, there was a collective sale of approval rights by cadres of the control center in Shangqiu City, southern province, with a total amount of more than 7.5 million yuan involved Recently, a deputy director of drug administration was detained for not repaying the loan It was revealed by the media that LV Huihe, deputy director of Yulin food and drug administration, borrowed money from drugstores in his own name and did not repay it for a long time In addition, LV Huihe also borrowed money from his colleagues and even from outsiders, which led to the SFDA being surrounded by his creditors for many times It has been confirmed that LV Hui and he were detained by the police on November 6 on suspicion of fraud But it is understood that Lv Hui and suspected of commitment to other arrangements, mobilization, adjustment work for fraud, the initial investigation of more than one million cases, the current police investigation does not include its large number of loans to pharmacies Pharmaceutical companies pay for the high price deposit, which industry people call "normal" Recently, Pingjiang County, Yueyang City, Hunan Province issued a bidding announcement on the open competition for the selection of cooperative enterprises for centralized procurement and distribution of pharmaceutical consumables According to the announcement, the quality assurance deposit purchased by the county's public hospitals is up to 100 million yuan in total, and the announcement also includes several situations in which the medical institutions deduct the quality assurance deposit For example, during the contract period, the enterprise is responsible for the maintenance of the software system and necessary upgrades free of charge If the enterprise defaults, the quality assurance deposit will be deducted by 10 million yuan; if the enterprise defaults for its own reasons, the quality assurance deposit will be deducted by 15 million yuan; if the enterprise distributes In case of any inconsistency between the drugs and the products required to be delivered by the medical institution, once it is found, it is required to deduct several provisions such as liquidated damages and other deductions from the deposit according to 10 times of the purchase amount of the medical institution In addition, the industry people also made an interpretation of the provisions of "secondary bargaining" in the announcement, that is, medical institutions and distribution enterprises work together to "secondary bargaining" for production enterprises, with more price reduction, and the excess money belongs to medical institutions, with less price reduction, and the lack of money is supplemented by distribution enterprises The above phenomenon of "margin collection" is just the "tip of the iceberg" in the pharmaceutical circle Earlier media reported that a well-known top three hospital in Jiangsu Province required to pay a certain proportion of the margin according to the sales volume of drugs, and stopped the drugs without the margin; the first people's Hospital of Hengyang City in Hunan Province also issued a notice, saying that the annual drug centralized distribution amount of the hospital was about 90 million, according to the comprehensive score Around 9 are the candidate distribution enterprises It is divided into 9 packages, each package is about 10 million yuan, with a contract period of 3 years, etc Information source: Yaozhi elite club, Yaozhi news, Cyprian blue, bureau of health and knowledge, hexun.com, medical community, food and drug law court and other statements: this point of view only represents the author, not the position of yaozhi.com, welcome to exchange and supplement in the message area; if you need to reprint, please be sure to indicate the author and source of the text.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.